TerrAscend

US Cannabis Legalization And Digital Health Will Unlock Opportunities

AnalystHighTarget

Not Invested

Consensus Narrative from 2 Analysts

Published

10 Aug 25

Updated

16 Aug 25

AnalystHighTarget's Fair Value

CA$2.25

39.2% undervalued

16 Aug

CA$1.37

-39.9%

33.0%

Author's Valuation

CA$2.3

39.2% undervalued

AnalystHighTarget Fair Value

Narrative

Updates0

AnalystHighTarget Fair Value

CA$2.3

39.2% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

4.10%

Pharma revenue growth rate

0.58%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.30%

Calculation

US$3.17m

Earnings '28

219.18x

PE Ratio '28

US$695.15m

Market Cap '28

US$695.15m

Market Cap '28

355.01m

No. shares '28

US$1.96

Share Price '28

US$1.96 Share Price '28

Discounted to 2025 @ 6.30% p.a.

US$1.63

Fair Value '25

US$1.63 Fair Value '25

Converted to CAD @ 1.3814 USD/CAD Exchange Rate

CA$2.25

Fair Value '25